CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Assess the key clinical variables that affect the use of preoperative therapy and the selection of specific therapeutic regimens for patients with HER2-overexpressing localized breast cancer, and integrate this information into treatment decision-making.
  • Evaluate published research data to guide the selection of adjuvant and/or extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer, incorporating existing and emerging targeted treatments.
  • Design an optimal approach to the care of patients with HER2-positive breast cancer and CNS metastases, considering the implications of prior therapeutic exposure, symptomatology and other factors.
  • Appraise available research data leading to the FDA approval of trastuzumab deruxtecan for HER2-positive metastatic breast cancer, and determine how this agent may be incorporated into clinical practice.
  • Consider the recent FDA approval of tucatinib with trastuzumab and capecitabine for previously treated advanced unresectable or metastatic HER2-positive breast cancer, including brain metastases, and identify patients who are appropriate candidates for treatment with this regimen.
  • Recognize the side effects associated with approved and investigational anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
  • Consider ongoing clinical research studies evaluating novel agents and treatment strategies under development for HER2-positive breast cancer, and counsel appropriate patients regarding the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Virginia F Borges, MD, MMSc
  Professor of Medicine with Tenure
  John C and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer
  Deputy Head, Division of Medical Oncology
  Director, Breast Cancer Research Program and
  Young Women’s Breast Cancer Translational Program
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Consulting Agreement: Seagen Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Pfizer Inc, Seagen Inc.
  
  Sara Hurvitz, MD
  Professor of Medicine
  David Geffen School of Medicine at UCLA
  Director, Breast Cancer Clinical Research Program
  Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
  Santa Monica, California
  
  Consulting Agreement (Stock Investment): NKMax America; Contracted Research: Ambrx Inc, Amgen Inc, Arvinas, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Dignitana, Genentech, a member of the Roche Group, GlaxoSmithKline, Immunomedics Inc, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Sanofi Genzyme, Seagen Inc, Zymeworks; Paid Travel: Lilly; Stocks (Spouse): IDEAL IMPLANT, ROMTech.
  
  Ian E Krop, MD, PhD
  Associate Chief, Division of Breast Oncology
  Dana-Farber Cancer Institute
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, MacroGenics Inc; Contracted Research: Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc, Taiho Oncology Inc; Data and Safety Board Monitoring Board/Committee: Merck, Novartis.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc and Seagen Inc.
  
  Release date: April 2021
  Expiration date: April 2022